

12-8128: Anti-Japanese Encephalitis Virus (Clone: JEV-69)

Clonality :	Monoclonal
Clone Name :	JEV-69
Application :	ELISA
Alternative Name :	JEV
Isotype :	Human IgG1
Immunogen Information :	A panel of human mAbs against JEV, including JEV-69, was generated from donors immunized with a GIII vaccine strain (JEV-SA14-14-2).

Description

Reactivity Species : Japanese Encephalitis-Virus
Expression Host : HEK-293
Endotoxin Level : ≤ 1.0 EU/mg as determined by the LAL method

Specificity : Clone JEV-69 activity is directed against DIII-LR of the E protein. JEV-69 has no cross-reactivity to West Nile Virus or Zika Virus E proteins.

Background : Japanese Encephalitis Virus (JEV) is a mosquito-borne, enveloped positive-stranded RNA virus in the Flavivirus genus endemic to Asia and parts of the western Pacific¹. Symptomatic JEV infection is most common in children in areas of endemicity or travelers to those regions. Severe symptoms occur in ~1% of cases, with a case-fatality ratio of 20–30%. Survivors often have neurologic, cognitive, or psychiatric sequelae issues. Five JEV genotypes have been identified, and existing vaccines are derived from historically predominant GIII strains².

Product Info

Amount :	100 μ g
Purification :	$\geq 95\%$ monomer by analytical SEC
Content :	≥ 5.0 mg/ml Formulation : This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added
Storage condition :	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at $\geq -70^\circ\text{C}$. Avoid Repeated Freeze Thaw Cycles.